Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 9/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24829093 | 0.91 | P2RY6 (0.40) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24828912 | 0.91 | P2RY6 (0.44) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829129 | 0.90 | P2RY6 (0.42) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829131 | 0.89 | P2RY6 (0.39) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24828984 | 0.89 | P2RY6 (0.39) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829180 | 0.89 | P2RY6 (0.39) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829130 | 0.89 | P2RY6 (0.39) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829127 | 0.89 | P2RY6 (0.39) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829151 | 0.88 | P2RY6 (0.41) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 | |
| SCHEMBL24829508 | 0.88 | P2RY6 (0.41) | P2RY6P2RY2P2RY4ALDH1A1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | Ascletis BioScience Co., Ltd (CN) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | P2RY6 731/4885P2RY2 1449/4885P2RY4 657/4885 |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | TYMP, NUDT1, PNP | P2RY6 731/4885P2RY2 1449/4885P2RY4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.